Epizyme, a clinical stage biopharmaceutical company focused on therapeutics for patients with...
Epizyme, a clinical stage biopharmaceutical company focused on therapeutics for patients with genetically defined cancers, files for a 4.285M share IPO. The company hasn't set an expected price range as of yet, but plans to list on the The Nasdaq Global Market under the symbol "EPZM." The offering will be made through Citigroup, Cowen, Leerink Swann, JMP Securities, and Wedbush PacGrow Life Sciences.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs